NHS Genomic Medicine Service - Most Suitable Provider Process
NHS EnglandEstimated Value
Up to £5,175,000,000
Deadline
Not specified
Published
23 October 2025
Type
services
Overview
This is a notice of intention to make an award in respect of the NHS Genomic Medicine Service pursuant to the Most Suitable Provider (MSP) Process for the NHS Genomic Medicine Service (NHS GMS). For the avoidance of doubt, this is an intention to award notice. A notice of the confirmation of the award of each contract will be issued once they are signed.
Key points
- Organisational leadership, governance and partnership arrangements;
- Delivery of genomic testing outlined in the National Genomic Test Directory (NGTD);
- Laboratory operating model;
- Clinical function: cancer genomics;
- Clinical function: rare disease;
- Clinical function: population health;
- Promotion of and supporting and leading where relevant science, research and / or innovation;
- Transformation and Service Improvement;
- People – workforce, education and training; and
- Data and digital
Key points
- Organisational leadership, governance and partnership arrangements;
- Delivery of genomic testing outlined in the National Genomic Test Directory (NGTD);
- Laboratory operating model;
- Clinical function: cancer genomics;
- Clinical function: rare disease;
- Clinical function: population health;
- Promotion of and supporting and leading where relevant science, research and / or innovation;
- Transformation and Service Improvement;
- People – workforce, education and training; and
- Data and digital The Commissioner intends to award contracts following the Most Suitable Process to 7 providers which are existing providers. This is an expansion of existing services which, under PSR, constitutes a new service. The approximate lifetime value of the contract for all Lots is £5,175,000,000. The services will start on 1st April 2026 and the initial period will run until 31st March 3034 with an option to extend for up to a further 2 years (of 2 x 12 month periods). Please note that the figure included in the 'Awarded Value' section of this part of the notice is the total approximate lifetime value of all Lots of the NHS Genomic Medicine Service contract. For the avoidance of doubt, this is not the approximate lifetime value for each Lot. The approximate lifetime value for each Lot shall be included within the confirmation of contract award notice (which shall be issued once contracts have been signed).
Key points
- Organisational leadership, governance and partnership arrangements;
- Delivery of genomic testing outlined in the National Genomic Test Directory (NGTD);
- Laboratory operating model;
- Clinical function: cancer genomics;
- Clinical function: rare disease;
- Clinical function: population health;
- Promotion of and supporting and leading where relevant science, research and / or innovation;
- Transformation and Service Improvement;
- People – workforce, education and training; and
- Data and digital The Commissioner intends to award contracts following the Most Suitable Process to 7 providers which are existing providers. This is an expansion of existing services which, under PSR, constitutes a new service. The approximate lifetime value of the contract for all Lots is £5,175,000,000. The services will start on 1st April 2026 and the initial period will run until 31st March 3034 with an option to extend for up to a further 2 years (of 2 x 12 month periods). Please note that the figure included in the 'Awarded Value' section of this part of the notice is the total approximate lifetime value of all Lots of the NHS Genomic Medicine Service contract. For the avoidance of doubt, this is not the approximate lifetime value for each Lot. The approximate lifetime value for each Lot shall be included within the confirmation of contract award notice (which shall be issued once contracts have been signed).
Key points
- Organisational leadership, governance and partnership arrangements;
- Delivery of genomic testing outlined in the National Genomic Test Directory (NGTD);
- Laboratory operating model;
- Clinical function: cancer genomics;
- Clinical function: rare disease;
- Clinical function: population health;
- Promotion of and supporting and leading where relevant science, research and / or innovation;
- Transformation and Service Improvement;
- People – workforce, education and training; and
- Data and digital The Commissioner intends to award contracts following the Most Suitable Process to 7 providers which are existing providers. This is an expansion of existing services which, under PSR, constitutes a new service. The approximate lifetime value of the contract for all Lots is £5,175,000,000. The services will start on 1st April 2026 and the initial period will run until 31st March 3034 with an option to extend for up to a further 2 years (of 2 x 12 month periods). Please note that the figure included in the 'Awarded Value' section of this part of the notice is the total approximate lifetime value of all Lots of the NHS Genomic Medicine Service contract. For the avoidance of doubt, this is not the approximate lifetime value for each Lot. The approximate lifetime value for each Lot shall be included within the confirmation of contract award notice (which shall be issued once contracts have been signed).
Key points
- Organisational leadership, governance and partnership arrangements;
- Delivery of genomic testing outlined in the National Genomic Test Directory (NGTD);
- Laboratory operating model;
- Clinical function: cancer genomics;
- Clinical function: rare disease;
- Clinical function: population health;
- Promotion of and supporting and leading where relevant science, research and / or innovation;
- Transformation and Service Improvement;
- People – workforce, education and training; and
- Data and digital The Commissioner intends to award contracts following the Most Suitable Process to 7 providers which are existing providers. This is an expansion of existing services which, under PSR, constitutes a new service. The approximate lifetime value of the contract for all Lots is £5,175,000,000. The services will start on 1st April 2026 and the initial period will run until 31st March 3034 with an option to extend for up to a further 2 years (of 2 x 12 month periods). Please note that the figure included in the 'Awarded Value' section of this part of the notice is the total approximate lifetime value of all Lots of the NHS Genomic Medicine Service contract. For the avoidance of doubt, this is not the approximate lifetime value for each Lot. The approximate lifetime value for each Lot shall be included within the confirmation of contract award notice (which shall be issued once contracts have been signed).
Key points
- Organisational leadership, governance and partnership arrangements;
- Delivery of genomic testing outlined in the National Genomic Test Directory (NGTD);
- Laboratory operating model;
- Clinical function: cancer genomics;
- Clinical function: rare disease;
- Clinical function: population health;
- Promotion of and supporting and leading where relevant science, research and / or innovation;
- Transformation and Service Improvement;
- People – workforce, education and training; and
- Data and digital The Commissioner intends to award contracts following the Most Suitable Process to 7 providers which are existing providers. This is an expansion of existing services which, under PSR, constitutes a new service. The approximate lifetime value of the contract for all Lots is £5,175,000,000. The services will start on 1st April 2026 and the initial period will run until 31st March 3034 with an option to extend for up to a further 2 years (of 2 x 12 month periods). Please note that the figure included in the 'Awarded Value' section of this part of the notice is the total approximate lifetime value of all Lots of the NHS Genomic Medicine Service contract. For the avoidance of doubt, this is not the approximate lifetime value for each Lot. The approximate lifetime value for each Lot shall be included within the confirmation of contract award notice (which shall be issued once contracts have been signed).
Key points
- Organisational leadership, governance and partnership arrangements;
- Delivery of genomic testing outlined in the National Genomic Test Directory (NGTD);
- Laboratory operating model;
- Clinical function: cancer genomics;
- Clinical function: rare disease;
- Clinical function: population health;
- Promotion of and supporting and leading where relevant science, research and / or innovation;
- Transformation and Service Improvement;
- People – workforce, education and training; and
- Data and digital The Commissioner intends to award contracts following the Most Suitable Process to 7 providers which are existing providers. This is an expansion of existing services which, under PSR, constitutes a new service. The approximate lifetime value of the contract for all Lots is £5,175,000,000. The services will start on 1st April 2026 and the initial period will run until 31st March 3034 with an option to extend for up to a further 2 years (of 2 x 12 month periods). Please note that the figure included in the 'Awarded Value' section of this part of the notice is the total approximate lifetime value of all Lots of the NHS Genomic Medicine Service contract. For the avoidance of doubt, this is not the approximate lifetime value for each Lot. The approximate lifetime value for each Lot shall be included within the confirmation of contract award notice (which shall be issued once contracts have been signed).
Key points
- Organisational leadership, governance and partnership arrangements;
- Delivery of genomic testing outlined in the National Genomic Test Directory (NGTD);
- Laboratory operating model;
- Clinical function: cancer genomics;
- Clinical function: rare disease;
- Clinical function: population health;
- Promotion of and supporting and leading where relevant science, research and / or innovation;
- Transformation and Service Improvement;
- People – workforce, education and training; and
- Data and digital The Commissioner intends to award contracts following the Most Suitable Process to 7 providers which are existing providers. This is an expansion of existing services which, under PSR, constitutes a new service. The approximate lifetime value of the contract for all Lots is £5,175,000,000. The services will start on 1st April 2026 and the initial period will run until 31st March 3034 with an option to extend for up to a further 2 years (of 2 x 12 month periods). Please note that the figure included in the 'Awarded Value' section of this part of the notice is the total approximate lifetime value of all Lots of the NHS Genomic Medicine Service contract. For the avoidance of doubt, this is not the approximate lifetime value for each Lot. The approximate lifetime value for each Lot shall be included within the confirmation of contract award notice (which shall be issued once contracts have been signed).
AI AnalysisMembers
Requirements, key tasks and tips for reading this tender — included with Tendarix membership.
£4.99/month after a 7-day free trial. Cancel anytime before it ends and you pay nothing.
Award Details
Manchester University NHS Foundation Trust
£5,175,000,000
The Newcastle upon Tyne Hospitals NHS Foundation Trust
£5,175,000,000
Birmingham Women’s and Children’s NHS Foundation Trust
£5,175,000,000
Cambridge University Hospitals NHS Foundation Trust
£5,175,000,000
North Bristol NHS Trust
£5,175,000,000
Great Ormond Street Hospital for Children NHS Foundation Trust
£5,175,000,000
Guy's and St Thomas' NHS Foundation Trust
£5,175,000,000
Likely incumbents
Suppliers who won similar work from this buyer in the last 5 years.
- 1
Sheffield Teaching Hospitals NHS Foundation Trust
4 contracts wonlatest 22 Sept 2026£780m
total awarded
- 2
The Newcastle upon Tyne Hospitals NHS Foundation Trust
4 contracts wonlatest 22 Sept 2026£794m
total awarded
- 3
CAMBRIDGE UNIVERSITY HOSPITALS NHS FOUNDATION TRUST
3 contracts wonlatest 7 Jul 2026£18m
total awarded
- 4
OXFORD UNIVERSITY HOSPITALS NHS FOUNDATION TRUST
3 contracts wonlatest 7 Jul 2026£32m
total awarded
- 5
MDSAS LTD
3 contracts wonlatest 19 Feb 2026£1m
total awarded
Sheffield Teaching Hospitals NHS Foundation Trust is the most likely incumbent based on recency and category match. To win, bidders typically need a clearly differentiated proposition or a price advantage.
Before you bid, buyers check
two years of filed accountsyour financial standingturnover vs contract valueyour Companies House recordcash flow for 30-day termscredit scores and ratios
Actions
Start free trialto open noticeStart free trial to downloadCreate an account and start a 7-day free trial to open the buyer’s own notice and tender documents, plus fit scoring and the Bid Writer. Then £4.99/month — cancel anytime.
Open Bid WriterIndependent software, web & cloud studio. We design, build and grow digital products that quietly outlast their category.
How to Apply
Step-by-step submission guide
Submission Portal
Find a Tender
Open the original notice
Click the button below to view the full notice on Find a Tender Service (FTS)
Check the procedure type
The "Procedure" section tells you if it's Open (one stage) or Restricted (SQ then ITT). This changes how you apply
Access the eSourcing portal
FTS notices link to the buyer's eSourcing platform — register there to access documents
Complete the Selection Questionnaire
Higher-value contracts often require an SQ first — this pre-qualifies you before the full bid stage
Submit electronically
Upload your completed response through the eSourcing platform before the closing date and time
FTS contracts are above UK procurement thresholds. Late submissions are strictly rejected — submit at least 24 hours before the deadline to avoid portal issues.
Buyer Profile
NHS EnglandKey Dates
Published
23 October 2025
Submission deadline
Not specified
Notice type
award
Source
find a tender
Related Tenders
All substance misuse
Barnsley Council has directly awarded a five‑year contract to Humankind Charity to run its community drug and alcohol treatment and recovery service (Barnsley Recovery Steps), the youth substance‑misuse service and to provide supported accommodation for people with multiple and complex needs aged 25 years and over.
Window to 1913: activity plan delivery lead
The Authority is now seeking a consultant to deliver the contents of the Activity and Interpretation Plans, to enable us to achieve the aims and objectives of the Window to 1913 pr
Soft market engagement - christmas market
Sheffield City Council is running a Soft Market Engagement to see if any suppliers can provide a Christmas market service. It’s not a formal tender – the council is just gathering information and checking interest before any contract is offered.
Insourced breast USC one-stop triple assessment and symptomatic breast radiology
Hull University Hospitals NHS Trust (HUTH) on behalf of the Humber Health Partnership (HHP) plan to work in partnership with an Independent Sector (IS) Provider to facilitate provi